Flexus Biosciences Inc

    [td_text_with_title custom_title=”Company description”]Founded in 2013, Flexus is a biotechnology company focused on the discovery, development, and commercialization of small-molecule cancer immunotherapies targeting regulatory T cells. The company is leveraging unexploited insights in immunology to discover Agents for Reversal of Tumor Immunosuppression (ARTIS). This disruptive approach to cancer therapy targets that which is common to all tumors, the host immune system.

    Flexus, located in San Carlos, CA, has raised $38M in funding from blue-chip investors Kleiner Perkins Caufield & Byers (KPCB), The Column Group (TCG), and Celgene. Flexus has assembled a management and R&D leadership team with a proven track record of success and an advisory group and team of scientists with unparalleled knowledge and expertise in drug discovery and translational sciences essential to execution of the ARTIS approach.[/td_text_with_title]

    Drugs

    Posts not found

    [td_text_with_title custom_title=”Latest post”]
    Flexus Biosciences takeover

    Flexus Biosciences takeover: Bristol-Myers Squibb To Expand Its Immuno-Oncology Pipeline

    NEW YORK & SAN CARLOS, Calif. — (BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) and Flexus Biosciences, Inc. announced today the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of Flexus, a privately held biotechnology company focused on the discovery and development of novel anti-cancer therapeutics. […]

    0 comments
    [/td_text_with_title]